Janney Montgomery Scott LLC lessened its holdings in shares of MediWound Ltd. (NASDAQ:MDWD – Free Report) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,801 shares of the biopharmaceutical company’s stock after selling 1,541 shares during the period. Janney Montgomery Scott LLC owned approximately 0.19% of MediWound worth $370,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in MDWD. MetLife Investment Management LLC acquired a new position in shares of MediWound during the 3rd quarter worth approximately $89,000. Barclays PLC grew its holdings in shares of MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 8,449 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of MediWound in the third quarter worth $212,000. State Street Corp raised its stake in MediWound by 219.6% in the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after purchasing an additional 45,529 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC lifted its position in MediWound by 8.5% during the fourth quarter. Silverberg Bernstein Capital Management LLC now owns 91,884 shares of the biopharmaceutical company’s stock worth $1,636,000 after purchasing an additional 7,200 shares during the period. 46.83% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of MediWound in a report on Friday, January 10th.
MediWound Stock Performance
Shares of MDWD stock opened at $17.54 on Tuesday. MediWound Ltd. has a fifty-two week low of $12.15 and a fifty-two week high of $24.00. The stock’s fifty day moving average price is $18.07 and its two-hundred day moving average price is $17.74. The company has a market cap of $189.26 million, a PE ratio of -6.05 and a beta of 0.81.
MediWound (NASDAQ:MDWD – Get Free Report) last released its quarterly earnings data on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period last year, the business earned ($0.24) earnings per share. On average, equities analysts predict that MediWound Ltd. will post -2.66 EPS for the current fiscal year.
MediWound Company Profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Featured Stories
- Five stocks we like better than MediWound
- What Are Dividend Champions? How to Invest in the Champions
- Merck: 4 No-Brainer Reasons to Buy This Dip
- What is a Secondary Public Offering? What Investors Need to Know
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- What does consumer price index measure?
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Want to see what other hedge funds are holding MDWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediWound Ltd. (NASDAQ:MDWD – Free Report).
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
